AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Tmunity Announces June 2019 Investor Conference Schedule

May 23, 2019

PHILADELPHIA--(BUSINESS WIRE)--May 23, 2019--

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at an investor conference in June 2019.

Jefferies 2019 Global Healthcare Conference
Thursday, June 6, 2019
9:30 a.m. ET
New York, NY

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005036/en/

CONTACT: Tmunity Contacts:

Investors:

Lisa A. Hayes

VP, Investor Relations and Corporate Communications

ir@tmunity.com

215-307-0458Media:

Mike Beyer, Sam Brown Inc.

mikebeyer@sambrown.com

312-961-2502

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Tmunity Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 05/23/2019 07:00 AM/DISC: 05/23/2019 07:01 AM

http://www.businesswire.com/news/home/20190523005036/en

All contents © copyright 2019 The Associated Press. All rights reserved.